Z22.7
Latent tuberculosis
Clinical Classification Guidelines
Inclusion Terms
- Latent tuberculosis infection (LTBI)
Excludes Type 1
- nonspecific reaction to cell mediated immunity measurement of gamma interferon antigen response without active tuberculosis (R76.12)
- nonspecific reaction to tuberculin skin test without active tuberculosis (R76.11)
Medical Intelligence & Overview
Latent tuberculosis infection (LTBI), classified under ICD-10 code Z22.7, occurs when a person is infected with the bacteria that cause tuberculosis (TB) but does not show symptoms and cannot spread the disease to others. Unlike active TB, latent TB is a dormant state where the bacteria remain inactive within the body, making it critical to recognize and manage to prevent potential future activation of the disease. This condition often remains unnoticed because individuals feel healthy and show no signs of illness, but they carry a risk of developing active TB later in life if not properly treated.
Causes & Symptoms
Clinical Causes: Inhalation of airborne droplets containing Mycobacterium tuberculosis from an individual with active TB Close contact with someone who has active tuberculosis Living in or frequently visiting areas with high TB prevalence Having a weakened immune system due to HIV, malnutrition, or other health conditions Previous exposure to TB bacteria, leading to latent infection
Key Symptoms: Generally asymptomatic; no symptoms are present Rarely, mild immune response signs such as fatigue Possible though uncommon: small, persistent cough or skin reactions No signs of illness or weight loss typical of active TB
Diagnostic & Treatment
Diagnosis Path: Latent tuberculosis is typically detected through specific tests since it doesn't produce symptoms. Common diagnostic methods include: - **Tuberculin Skin Test (TST):** A small amount of tuberculin purified protein derivative (PPD) is injected under the skin; swelling indicates possible LTBI. - **Interferon-Gamma Release Assays (IGRAs):** Blood tests measuring immune responses to TB bacteria. Further testing may include chest X-rays to rule out active TB infection, though they usually appear normal in latent cases. Confirming LTBI involves ruling out active disease, as the presence of symptoms or abnormal imaging suggests active TB rather than latent infection.
Treatment Protocols: While latent TB does not require immediate treatment for symptoms, preventing its progression to active TB is important. Treatment options typically involve: - **Antituberculous medications:** Common regimens include isoniazid taken daily for 6 to 9 months or a combination of rifampin for 4 months. - **Monitoring:** Regular follow-up to ensure adherence to treatment and to check for side effects. Addressing risk factors, such as immune system health, and ensuring close contact tracing are also vital steps in managing LTBI. Adherence to treatment is essential to eliminate the bacteria and prevent future active TB development.
Clinical Advice & FAQs
Billing Guidance
Is Z22.7 a billable ICD-10 code?
Yes, Z22.7 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z22.7?
Clinical documentation must specify the nature of Latent tuberculosis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference